Unknown

Dataset Information

0

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).

ABSTRACT:

SUBMITTER: Jacoby MA 

PROVIDER: S-EPMC9102836 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).

Jacoby Meagan A MA   Finn Laura L   Emadi Ashkan A   Saba Nakhle S NS   Powell Bayard L BL   Seiter Karen K   Garcia Rosella R   Faderl Stefan S   Male Heather J HJ  

Leukemia & lymphoma 20210511 10

Similar Datasets

Unknown Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
| S-EPMC11699081 | biostudies-literature
Unknown Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351∗
| S-EPMC12915183 | biostudies-literature
Unknown CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies.
| S-EPMC8791570 | biostudies-literature
Unknown Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.
| S-EPMC9631647 | biostudies-literature
Unknown Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
| S-EPMC7993093 | biostudies-literature
Unknown V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.
| S-EPMC12418821 | biostudies-literature
Unknown CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
| S-EPMC11829133 | biostudies-literature
Unknown Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes.
| S-EPMC6306103 | biostudies-literature
Unknown Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
| S-EPMC8276472 | biostudies-literature
Unknown A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia.
| S-EPMC12542300 | biostudies-literature